Physician profile
Leah Robinowitz
NPI 1891056123
$1,932.67
in general payments reported to CMS, 2019-2025
19 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2023: $125 · 2024: $927 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $546.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $251.14 | 2024-2025 | Veozah |
| Lilly USA, LLC | $187.79 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $128.30 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Vivus LLC | $124.97 | 2023 | Qsymia |
| Sanofi-Aventis U.S. LLC | $108.24 | 2024 | |
| Pfizer INC. | $93.75 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $81.87 | 2024 | |
| Sumitomo Pharma America, INC. | $62.09 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $52.27 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $51.64 | 2025 | |
| Dynavax Technologies Corporation | $49.12 | 2024 | Heplisav-B |
| Glaxosmithkline, LLC. | $47.66 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $41.69 | 2025 | |
| Hologic Sales and Service, LLC | $24.45 | 2024 | Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $23.28 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $22.55 | 2024 | Austedo Xr |
| Actelion Pharmaceuticals US, INC. | $19.19 | 2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $16.62 | 2025 | Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Robinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.